IP Verse

Crystals - EP2447254

The patent EP2447254 was granted to Nippon Shinyaku on Dec 6, 2017. The application was originally filed on Jun 25, 2010 under application number EP10792183A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2447254

NIPPON SHINYAKU
Application Number
EP10792183A
Filing Date
Jun 25, 2010
Status
Opposition Rejected
Jul 5, 2024
Publication Date
Dec 6, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HEXALSep 5, 2018TER MEER STEINMEISTER & PARTNERADMISSIBLE
GENERICS UKSep 4, 2018ELKINGTON AND FIFEADMISSIBLE
ALFRED E TIEFENBACHERSep 3, 2018HAMM & WITTKOPPADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO02088084
DESCRIPTIONWO2009107736
DESCRIPTIONWO2009154246
DESCRIPTIONWO2009157396
DESCRIPTIONWO2009157397
DESCRIPTIONWO2009157398
INTERNATIONAL-SEARCH-REPORTEP1400518
INTERNATIONAL-SEARCH-REPORTWO2009107736
INTERNATIONAL-SEARCH-REPORTWO2009154246
INTERNATIONAL-SEARCH-REPORTWO2009157396
INTERNATIONAL-SEARCH-REPORTWO2009157397
INTERNATIONAL-SEARCH-REPORTWO2009157398
OPPOSITIONEP1400518

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- ANDERTON C., "A valuable technique for polymorph screening", European Pharmaceutical Review, (20040000), vol. 9, no. 2, pages 68 - 74, XP002538579
OPPOSITION- "Chapter 5", H. G. Brittain, Polymorphism in Pharmaceutical Solids, (19990000), pages 183 - 226, XP055517836
OPPOSITION- "Chapters 1 and 5", H.G. Brittain, Polymorphism in Pharmaceutical solids, (19990000), vol. 95, pages 1 - 33, 183-226, XP055517836
OPPOSITION- John F. Bauer, "Polymorphism - A Critical Consideration in Pharmaceutical Development, Manufacturing, and Stability", Journal of Validation Technology, (20080000), pages 15 - 23, XP055517809
OPPOSITION- Leonard, Lygo and Procter, Advanced Practical Organic Chemistry, 2nd ed., (19950000), pages 184 - 187, XP055378678
OPPOSITION- Rolf Hilfiker, Polymorphism in the Pharmaceutical Industry, Weinheim, Wiley VCH, (20060000), pages 7 - 12, 211, 212, XP055518266
OPPOSITION- M. R. CAIRA, "Crystalline Polymorphism of Organic Compounds", Topics in Current Chemistry, (19980000), vol. 198, pages 163 - 208, XP008166276
OPPOSITION- Asaki et al., "Structure-activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists", Bioorganic & Medicinal Chemistry, vol. 15, (20070000), pages 6692 - 6704, XP022244799
OPPOSITION- T. ASAKI et al., "Structure-activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists", Bioorganic & Medicinal Chemistry, (20070000), vol. 15, pages 6692 - 6704, XP022244799
OPPOSITION- A. NAKAMURA et al., "Synthesis and evaluation of N-acylsulfonamide and N- acylsulfonylurea prodrugs of a prostacyclin receptor agonist", Bioorganic & Medic- inal Chemistry, (20070000), vol. 15, pages 7720 - 7725, XP022302066
OPPOSITION- W. I. CROSS et al., "A Whole Output Strategy for Polymorph Screening: Combining Crystal Structure Prediction, Graph Set Analysis, and Targeted Crystallization Ex- periments in the Case of Diflunisal", Crystal Growth & Design, (20030000), vol. 3, no. 2, pages 151 - 158, XP055518274
OPPOSITION- Byrn et al, "PHARMACEUTICAL SOLIDS: A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS", Pharmaceutical Research, (19950000), vol. 12, no. 7, pages 945 - 954, XP000996386
OPPOSITION- S BYRN et al, "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", Pharmaceutical Research, (19950000), vol. 12, no. 7, pages 945 - 954, XP000996386
OPPOSITION- K. KUWANO et al., "2-(4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino] bu- tyloxy)-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long- Acting Prostacyclin Receptor Agonist Prodrug", The Journal of Pharmacology and Experimental Therapeutics, (20070000), vol. 322, no. 3, pages 1181 - 1188, XP002670411
OPPOSITION- Kuwano et al., "2-{4-[5,6-(Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N- (methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 322, no. 3, (20070000), pages 1181 - 1188, XP002670411
SEARCH[ ] - No further relevant documents disclosed

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents